Please login to the form below

Not currently logged in
Email:
Password:

FDA accepts new diabetes compound NDA

The US FDA has accepted a new drug application for dapagliflozin, an investigational type 2 diabetes compound, from AstraZeneca and Bristol-Myers Squibb

The US Food and Drug Administration (FDA) has accepted for review a new drug application (NDA) for dapagliflozin, an investigational type 2 diabetes compound, from AstraZeneca (AZ) and Bristol-Myers Squibb (BMS). The European Medicines Agency (EMA) has also validated a marketing authorisation application (MAA) for the compound. 

Both submissions include data gathered during a two-year period from a global development programme involving approximately 6,000 individuals in 40 clinical studies. To comply with FDA guidelines, the US submission also includes data assessing the cardiovascular safety of dapagliflozin in adults with type 2 diabetes.

Dapagliflozin is designed to help control glycaemia independently of insulin pathways. It works by inhibiting sodium-glucose cotransporter-2 (SGLT2) – a specific target located in the kidney, leading to the excretion of excess glucose and associated calories in the urine.

The development of dapagliflozin is the result of a collaboration deal formed between AZ and BMS in 2007 to enable the companies to research, develop and commercialise select investigational drugs for type 2 diabetes.

According to the International Diabetes Federation (IDF), around 285 million people globally have diabetes. This figure is projected to increase to 438m by 2030.

8th March 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Collected Group

Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...

Latest intelligence

Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.
Here are 5 healthcare marketing blunders and how best to avoid them....